Abbott Laboratories (ABT) | Financial Analysis & Statements

Abbott Laboratories | Mega-cap | Healthcare

134,01 US$

-1,19 %

| Abbott Laboratories Stock Comparison:

Abbott Laboratories vs Boston Scientific Abbott Laboratories vs Stryker Abbott Laboratories vs Medtronic plc Abbott Laboratories vs Edwards Lifesciences Abbott Laboratories vs Dexcom Abbott Laboratories vs S&P 500 | Market

Overview Income Statement Balance Sheet Cash Flow Key Ratios Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 42,0B

Gross Profit 23,2B 55,41 %

Operating Income 6,8B 16,27 %

Net Income 13,4B 31,95 %

EPS (Diluted) 7,64 US$

Balance Sheet Metrics

Total Assets 81,4B

Total Liabilities 33,5B

Shareholders Equity 47,9B

Debt to Equity 0,70

Cash Flow Metrics

Operating Cash Flow 16,9B

Free Cash Flow 6,4B

Revenue & Profitability Trend

Income Statement

Metric	2024	2023	2022	2021	2020
Revenue	42,0B	40,1B	43,7B	43,1B	34,6B
Cost of Goods Sold	18,7B	18,0B	19,1B	18,5B	15,0B
Gross Profit	23,2B	22,1B	24,5B	24,5B	19,6B
Operating Expenses	14,5B	13,7B	14,1B	14,1B	12,1B
Operating Income	6,8B	6,5B	8,4B	8,4B	5,4B
Pre-tax Income	7,0B	6,7B	8,3B	8,2B	5,0B
Income Tax	-6,4B	941,0M	1,4B	1,1B	497,0M
Net Income	13,4B	5,7B	6,9B	7,1B	4,5B
EPS (Diluted)	7,64 US$	3,26 US$	3,91 US$	3,94 US$	2,50 US$

Income Statement Trend

Balance Sheet

Metric	2024	2023	2022	2021	2020
Assets
Current Assets	23,7B	22,7B	25,2B	24,2B	20,4B
Non-Current Assets	57,8B	50,5B	49,2B	51,0B	52,1B
Total Assets	81,4B	73,2B	74,4B	75,2B	72,5B
Liabilities
Current Liabilities	14,2B	13,8B	15,5B	13,1B	11,9B
Non-Current Liabilities	19,4B	20,5B	22,0B	26,1B	27,6B
Total Liabilities	33,5B	34,4B	37,5B	39,2B	39,5B
Equity
Total Shareholders Equity	47,9B	38,8B	36,9B	36,0B	33,0B

Balance Sheet Composition

Cash Flow Statement

Metric	2024	2023	2022	2021	2020
Operating Activities
Net Income	13,4B	5,7B	6,9B	7,1B	4,5B
Operating Cash Flow	16,9B	7,7B	9,4B	10,8B	8,7B
Investing Activities
Capital Expenditures	-2,2B	-2,2B	-1,8B	-1,9B	-2,2B
Investing Cash Flow	-2,3B	-3,1B	-1,7B	-2,0B	-2,2B
Financing Activities
Dividends Paid	-3,8B	-3,6B	-3,3B	-3,2B	-2,6B
Financing Cash Flow	-5,7B	-7,3B	-7,8B	-5,7B	-3,0B
Free Cash Flow	6,4B	5,1B	7,8B	8,6B	5,7B

Cash Flow Trend

Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 17,38

Forward P/E 25,94

Price to Book 4,77

Price to Sales 5,50

PEG Ratio 25,94

Profitability Ratios

Profit Margin 31,89 %

Operating Margin 18,09 %

Return on Equity 30,65 %

Return on Assets 6,38 %

Financial Health

Current Ratio 1,78

Debt to Equity 27,09

Beta 0,74

Per Share Data

EPS (TTM) 7,70 US$

Book Value per Share 28,06 US$

Revenue per Share 24,34 US$

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
abt	232,9B	17,38	4,77	30,65 %	31,89 %	27,09
Boston Scientific	147,6B	72,80	6,64	9,50 %	11,58 %	52,16
Stryker	144,2B	50,99	6,89	14,26 %	12,31 %	82,92
Medtronic plc	111,9B	24,17	2,33	9,51 %	13,90 %	59,09
Edwards Lifesciences	44,1B	31,05	4,35	16,51 %	75,71 %	6,86
Dexcom	32,1B	61,65	14,18	23,72 %	12,90 %	113,97

Financial data is updated regularly. All figures are in the company's reporting currency.